[go: up one dir, main page]

CL2018003489A1 - Composición y método para reducir neutropenia - Google Patents

Composición y método para reducir neutropenia

Info

Publication number
CL2018003489A1
CL2018003489A1 CL2018003489A CL2018003489A CL2018003489A1 CL 2018003489 A1 CL2018003489 A1 CL 2018003489A1 CL 2018003489 A CL2018003489 A CL 2018003489A CL 2018003489 A CL2018003489 A CL 2018003489A CL 2018003489 A1 CL2018003489 A1 CL 2018003489A1
Authority
CL
Chile
Prior art keywords
composition
neutropenia
administration
reduce neutropenia
reduce
Prior art date
Application number
CL2018003489A
Other languages
English (en)
Inventor
Lan Huang
George Kenneth Lloyd
Ramon Mohanlal
Original Assignee
Beyondspring Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beyondspring Pharmaceuticals Inc filed Critical Beyondspring Pharmaceuticals Inc
Publication of CL2018003489A1 publication Critical patent/CL2018003489A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

METODO DE REDUCCION DE LA NEUTROPENIA QUE COMPRENDE LA ADMINISTRACION DE PLINABULINA, O ALGUNA DE SUS SALES, DONDE LA NEUTROPENIA ES PROVOCADA POR LA ADMINISTRACION DE UNA PRIMERA COMPOSICION QUIMIOTERAPEUTICA QUE COMPRENDE UNO O MAS AGENTES QUIMIOTERAPEUTICOS Y NO COMPRENDE DOCETAXEL, O POR LA ADMINISTRACION DE RADIOTERAPIA.
CL2018003489A 2016-06-06 2018-12-05 Composición y método para reducir neutropenia CL2018003489A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346426P 2016-06-06 2016-06-06
US201762454628P 2017-02-03 2017-02-03

Publications (1)

Publication Number Publication Date
CL2018003489A1 true CL2018003489A1 (es) 2019-02-01

Family

ID=60578094

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003489A CL2018003489A1 (es) 2016-06-06 2018-12-05 Composición y método para reducir neutropenia

Country Status (14)

Country Link
US (2) US11229642B2 (es)
EP (1) EP3463337A4 (es)
JP (3) JP7025416B2 (es)
KR (3) KR20190015361A (es)
CN (2) CN118304304A (es)
AU (1) AU2017278245B2 (es)
BR (1) BR112018074990A2 (es)
CL (1) CL2018003489A1 (es)
IL (1) IL263439B2 (es)
MX (1) MX389200B (es)
RU (1) RU2760348C2 (es)
SG (1) SG11201810872UA (es)
TW (1) TWI777957B (es)
WO (1) WO2017214052A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
KR102680823B1 (ko) 2015-07-13 2024-07-03 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 조성물
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
CN118304304A (zh) * 2016-06-06 2024-07-09 大连万春布林医药有限公司 用于减少中性粒细胞减少症的组合物和方法
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (ja) * 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法
EP3743074A4 (en) * 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
KR20200116477A (ko) * 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
US20240299377A1 (en) * 2019-10-15 2024-09-12 Beyondspring Pharmaceuticals, Inc. Methods and compositions for treating iron disorders
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
WO2023274316A1 (zh) * 2021-06-29 2023-01-05 深圳华泓海洋生物医药有限公司 氘代普那布林在制备治疗中性粒细胞减少症药物中的应用
CN113456643B (zh) * 2021-08-11 2022-04-01 遵义医科大学 一种含普那布林的药物组合及其应用
CN117860672A (zh) 2022-10-11 2024-04-12 大连万春布林医药有限公司 一种普那布林胶束组合物及其制备方法

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0022229B1 (en) 1979-06-29 1982-12-08 The Wellcome Foundation Limited Substituted phenol ethers, their preparation, intermediates therefor, pharmaceutical compositions containing them and the preparation thereof
IT1193786B (it) 1980-12-18 1988-08-24 Wellcome Found Composti eterei dotati di attivita' mitigatrice delle emoglobinopatie intermedi e procedimento per la loro preparazione
AU576322B2 (en) 1983-07-22 1988-08-25 Ici Australia Limited Alpha-substituted-alpha-cyanomethyl alcohols
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
JPH05255106A (ja) 1990-10-31 1993-10-05 Toray Ind Inc 血小板減少症治療剤
JPH059164A (ja) 1991-07-02 1993-01-19 Sumitomo Chem Co Ltd 光学活性マンデロニトリル誘導体の製造方法
GB9217331D0 (en) 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
US6096786A (en) 1992-10-01 2000-08-01 Glaxo Wellcome Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
US5872151A (en) 1992-10-01 1999-02-16 Glaxo Wellcome Inc. Immunopotentiatory agents and physiologically acceptable salts thereof
DE69306545T2 (de) 1992-10-01 1997-04-03 Wellcome Found Tucaresol als Mittel zur Immunopotentierung
CA2149150C (en) 1992-11-27 2000-08-01 David R. Carver Injectable taxol composition with improved stability
JPH0725858A (ja) 1993-07-13 1995-01-27 Otsuka Pharmaceut Co Ltd ピペラジン誘導体
US5958980A (en) 1993-08-26 1999-09-28 Glaxo Wellcome, Inc. Immunopotentiatory agent and physiologically acceptable salts thereof
IL110787A0 (en) 1993-08-27 1994-11-11 Sandoz Ag Biodegradable polymer, its preparation and pharmaceutical composition containing it
GB9402807D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402809D0 (en) 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9426224D0 (en) 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
US5874443A (en) 1995-10-19 1999-02-23 Trega Biosciences, Inc. Isoquinoline derivatives and isoquinoline combinatorial libraries
US5886210A (en) 1996-08-22 1999-03-23 Rohm And Haas Company Method for preparing aromatic compounds
JP3131574B2 (ja) 1996-09-04 2001-02-05 新日本製鐵株式会社 新規抗腫瘍物質、該物質を製造するための微生物及び方法、並びに該物質を有効成分とする細胞周期阻害剤及び抗腫瘍剤
US5939098A (en) 1996-09-19 1999-08-17 Schering Corporation Cancer treatment with temozolomide
US5922683A (en) 1997-05-29 1999-07-13 Abbott Laboratories Multicyclic erythromycin derivatives
AUPO735997A0 (en) 1997-06-17 1997-07-10 Fujisawa Pharmaceutical Co., Ltd. Piperazine derivatives
US6479484B1 (en) 1997-11-21 2002-11-12 Euro-Celtique S.A. Substituted 2-aminoacetamides and the use thereof
KR20010034469A (ko) 1998-01-29 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 Ｎ-[(지방족 또는 방향족)카보닐]-2-아미노아세트아미드화합물 및 환화 화합물의 제조방법
US7141603B2 (en) 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6069146A (en) 1998-03-25 2000-05-30 The Regents Of The University Of California Halimide, a cytotoxic marine natural product, and derivatives thereof
KR20010041705A (ko) 1998-03-26 2001-05-25 시오노 요시히코 항바이러스성 활성을 가진 인돌 유도체
US6509331B1 (en) 1998-06-22 2003-01-21 Elan Pharmaceuticals, Inc. Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
GB9818627D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Improvements in dva vaccination
FR2784988B1 (fr) 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7026322B2 (en) 1998-11-12 2006-04-11 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
US6358957B1 (en) 1998-11-12 2002-03-19 Nereus Pharmaceuticals, Inc. Phenylahistin and the phenylahistin analogs, a new class of anti-tumor compounds
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
AU784062B2 (en) 1999-08-23 2006-01-19 Dana-Farber Cancer Institute, Inc. Novel B7-4 molecules and uses therefor
ES2629683T3 (es) 1999-11-30 2017-08-14 Mayo Foundation For Medical Education And Research B7-H1, una nueva molécula inmunorreguladora
BR0017067A (pt) 2000-01-18 2002-10-22 Nereus Pharmaceuticals Inc Inibidor de divisão de célula, desidrogenase, método para a produção de um inibidor de divisão de célula e composto
EP1265840A2 (en) 2000-03-17 2002-12-18 Corixa Corporation Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors
US6635649B2 (en) 2000-05-09 2003-10-21 Che-Ming Teng Piperazinedione compounds
WO2002064592A1 (en) 2000-12-28 2002-08-22 Neurocrine Biosciences, Inc. Tricyclic crf receptor antagonists
US20030082140A1 (en) 2001-08-20 2003-05-01 Fisher Paul B. Combinatorial methods for inducing cancer cell death
AU2003213673A1 (en) 2002-03-01 2003-09-16 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
ME00055B (me) 2002-05-17 2010-10-10 Aventis Pharma Sa Primjena docetaksel/doksorubicin/ciklofosfamida u adjuvantnoj terapiji raka dojke i jajnika
US7012100B1 (en) 2002-06-04 2006-03-14 Avolix Pharmaceuticals, Inc. Cell migration inhibiting compositions and methods and compositions for treating cancer
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
ES2295695T3 (es) 2002-08-02 2008-04-16 Nereus Pharmaceuticals, Inc. Deshidrofenilahistinas y sus analogos y la sintesis de deshidrofenilahistinas y sus analogos.
SE0202429D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel Compounds
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20040197312A1 (en) 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
CA2553630A1 (en) 2004-02-04 2005-08-25 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
PL1740593T3 (pl) 2004-04-19 2016-09-30 Sposoby wytwarzania wodorosiarczanu klopidogrelu w formie polimorficznej I
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CN101248089A (zh) 2005-07-01 2008-08-20 米德列斯公司 抗程序性死亡配体1（pd-l1）的人单克隆抗体
WO2007035841A1 (en) 2005-09-21 2007-03-29 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US20090130098A1 (en) 2006-01-18 2009-05-21 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
WO2007113648A2 (en) 2006-04-05 2007-10-11 Pfizer Products Inc. Ctla4 antibody combination therapy
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
AU2008216669B2 (en) 2007-02-15 2013-12-12 Mannkind Corporation A method for enhancing T cell response
WO2008128169A1 (en) 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
US20090170837A1 (en) 2007-08-17 2009-07-02 Thallion Pharmaceuticals Inc. Methods for treating ras driven cancer in a subject
US8569262B2 (en) 2007-11-02 2013-10-29 Momenta Pharmaceuticals, Inc. Polysaccharide compositions and methods of use for the treatment and prevention of disorders associated with progenitor cell mobilization
JP2011503071A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる子宮がん及び卵巣がんの治療
CN101909693A (zh) 2008-01-08 2010-12-08 百时美施贵宝公司 用于治疗增殖性疾病的抗-ctla4抗体与微管蛋白调节剂的组合
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
JP5753095B2 (ja) 2009-01-16 2015-07-22 テバ ファーマシューティカル インダストリーズ リミテッド 組換えヒトアルブミン−ヒト顆粒球コロニー刺激因子融合タンパク質の安定な製剤
CA2754217A1 (en) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Methods and systems for treatment and/or diagnosis
WO2010114922A1 (en) 2009-03-31 2010-10-07 Agios Pharmaceuticals, Inc. Methods of treating cancer having an aberrant egfr or kras genotype
GB0907551D0 (en) 2009-05-01 2009-06-10 Univ Dundee Treatment or prophylaxis of proliferative conditions
PT2464218E (pt) 2009-08-10 2015-09-16 Univ Texas Tratamento de metástases do cérebro com inibidores de recetores de endotelina, em combinação com um agente quimioterapêutico citotóxico
CA2939165A1 (en) 2009-09-15 2011-03-24 Cerulean Pharma Inc. A cdp-camptothecin conjugate, particle or composition and uses thereof
US20120114658A1 (en) 2009-09-15 2012-05-10 John Ryan Treatment of cancer
JP2013508415A (ja) 2009-10-23 2013-03-07 マンカインド コーポレイション 癌の免疫療法、および治療の方法
SI3279215T1 (sl) 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
CN101766815B (zh) 2009-12-31 2012-04-25 胡松华 紫杉醇及多西紫杉醇的用途
US20130225424A1 (en) 2010-03-03 2013-08-29 Targeted Molecular Diagnostics, Llc Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification
EP2571577A1 (en) 2010-05-17 2013-03-27 Bristol-Myers Squibb Company Improved immunotherapeutic dosing regimens and combinations thereof
CA2799653A1 (en) 2010-06-04 2011-12-08 Bertrand Leblond Substituted isoquinolines and their use as tubulin polymerization inhibitors
JP2012033526A (ja) 2010-07-28 2012-02-16 Fuji Electric Co Ltd 薄膜太陽電池およびその製造方法
WO2012035436A1 (en) 2010-09-15 2012-03-22 Tokyo University Of Pharmacy And Life Sciences Plinabulin prodrug analogs and therapeutic uses thereof
US20120214679A1 (en) 2010-11-29 2012-08-23 Precision Therapeutics, Inc. Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
TWI386203B (zh) 2011-01-07 2013-02-21 Univ China Medical 治療腦癌或用以降低腦癌細胞對替莫唑胺之抗藥性之醫藥組合物及其應用
PL2699264T3 (pl) 2011-04-20 2018-08-31 Medimmune, Llc Przeciwciała i inne cząsteczki wiążące B7-H1 i PD-1
EP2786140A4 (en) 2011-11-28 2015-10-28 Nat Res Council Canada PACLITAXEL REACTION MARKERS FOR CANCER
WO2013090552A1 (en) 2011-12-13 2013-06-20 Yale University Compositions and methods for reducing ctl exhaustion
WO2013124867A1 (en) 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
CN104411316B (zh) 2012-05-09 2018-05-01 坎泰克斯制药股份有限公司 骨髓抑制的治疗
AU2013204313C1 (en) 2012-06-01 2016-04-07 Bionomics Limited Combination Therapy
HK1211601A1 (en) 2012-08-30 2016-05-27 埃姆艮股份有限公司 A method for treating melanoma using a herpes simplex virus and an immune checkpoint inhibitor
US9168739B2 (en) * 2012-09-25 2015-10-27 Hewlett-Packard Development Company, L.P. Print head die
WO2014066834A1 (en) 2012-10-26 2014-05-01 The University Of Chicago Synergistic combination of immunologic inhibitors for the treatment of cancer
MX374929B (es) 2013-02-20 2025-03-06 Novartis Ag RECEPTOR QUIMERICO DE ANTIGENO anti-EGFRvlll HUMANIZADO Y USOS DEL MISMO.
WO2014160183A1 (en) 2013-03-13 2014-10-02 The United States Of America,As Represented By The Secretary,Department Of Health And Human Services Methods for modulating chemotherapeutic cytotoxicity
TWI639449B (zh) 2013-03-15 2018-11-01 美商安美基公司 用於注射器之匣盒
JP6526627B2 (ja) 2013-04-24 2019-06-05 テル ハショメール メディカル リサーチ インフラストラクチャー アンド サービシズ リミテッド 組織解析用の磁気共鳴マップ
JP6603209B2 (ja) 2013-05-10 2019-11-06 ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ ソルターゼ（Ｓｏｒｔａｓｅ）を用いた生存細胞のタンパク質修飾
JP2016520643A (ja) 2013-06-03 2016-07-14 ノバルティス アーゲー 抗ｐｄ−ｌ１抗体とｍｅｋ阻害薬および／またはｂｒａｆ阻害薬の組み合わせ物
JP6311097B2 (ja) 2013-07-31 2018-04-18 学校法人東京薬科大学 微小管脱重合剤
DK3076972T3 (da) 2013-10-11 2022-01-03 Beyondspring Inc Cancerbehandling med kombination af plinabulin og taxan
BR112016010224A2 (pt) 2013-11-05 2018-05-02 Cognate Bioservices, Inc. combinações de inibidores do ponto de verificação e produtos terapêuticos para tratar o câncer.
EP3594359B1 (en) 2013-11-06 2022-05-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Method for subtyping lymphoma types by means of expression profiling
CN104796448B (zh) * 2014-01-22 2019-02-12 腾讯科技（深圳）有限公司 网络系统的数据处理方法和装置
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US10238630B2 (en) 2014-05-28 2019-03-26 Eisai R&D Management Co., Ltd. Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer
WO2016019472A1 (en) 2014-08-08 2016-02-11 Quest Pharmatech Inc. Tumor antigen specific antibodies and tlr3 stimulation to enhance the performance of checkpoint interference therapy of cancer
WO2016081281A1 (en) 2014-11-17 2016-05-26 Salk Institute For Biological Studies Lipophilic bisphosphonates and methods of use
CA2975729A1 (en) 2015-02-12 2016-08-18 Beyondspring Pharmaceuticals, Inc. Use of plinabulin in combination with immune checkpoint inhibitors
RU2728796C2 (ru) 2015-03-06 2020-07-31 Бейондспринг Фармасьютикалс, Инк. Способ лечения опухоли головного мозга
JP6769982B2 (ja) 2015-03-06 2020-10-14 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Ｒａｓ変異と関連するがんの治療方法
WO2016165007A1 (en) 2015-04-17 2016-10-20 The University Of British Columbia Inhibitors of estrogen receptor alpha and their use as therapeutics for cancer
CN106279039B (zh) 2015-06-02 2019-01-11 青岛海洋生物医药研究院股份有限公司 氘代脱氢苯基阿夕斯丁类化合物及其制备方法和在制备抗肿瘤的药物中的应用
KR102680823B1 (ko) 2015-07-13 2024-07-03 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 조성물
EP3359692A4 (en) 2015-10-05 2019-05-01 Cedars-Sinai Medical Center METHOD FOR CLASSIFYING AND TREATING CANCER
BR112018016054A2 (pt) 2016-02-08 2019-02-12 Beyondspring Pharmaceuticals, Inc. composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
CN118304304A (zh) * 2016-06-06 2024-07-09 大连万春布林医药有限公司 用于减少中性粒细胞减少症的组合物和方法
JP6779517B2 (ja) 2016-09-02 2020-11-04 国立大学法人 鹿児島大学 抗癌剤の感受性及び癌の予後に対する診断マーカー
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
JP2020514412A (ja) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド 好中球減少症の低減方法
BR112019018880A2 (pt) 2017-03-13 2020-04-14 Beyondspring Pharmaceuticals Inc composições de plinabulina e seu uso
US10933061B2 (en) 2017-12-21 2021-03-02 Shepherd Therapeutics, Inc. Pyrvinium pamoate therapies and methods of use
EP3743074A4 (en) 2018-01-24 2021-12-15 Beyondspring Pharmaceuticals Inc. COMPOSITION AND METHOD FOR REDUCING THROMBOCYTOPENIA BY THE ADMINISTRATION OF PLINABULINE
KR20200116477A (ko) 2018-02-01 2020-10-12 비욘드스프링 파마수티컬스, 인코포레이티드. 플리나불린 및 g-csf 제제의 투여를 통해 화학요법-유도된 호중구감소증을 감소시키기 위한 조성물 및 방법
CN110240592A (zh) 2018-03-08 2019-09-17 青岛海洋生物医药研究院股份有限公司 (z)-3-(3-甲酰基苯亚甲基)哌嗪二酮类化合物及其在制备抗肿瘤药物中的应用
CA3095709A1 (en) 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
US20210161888A1 (en) 2018-06-01 2021-06-03 Beyondspring Pharmaceuticals, Inc. Composition and method of treating cancer associated with egfr mutation
MX2021001762A (es) 2018-08-16 2021-04-19 Beyondspring Pharmaceuticals Inc Metodo y composicion para estimular la respuesta inmunitaria.
CN113661253B (zh) 2018-11-14 2024-03-12 大连万春布林医药有限公司 微管蛋白结合剂治疗癌症的方法
US20240299377A1 (en) 2019-10-15 2024-09-12 Beyondspring Pharmaceuticals, Inc. Methods and compositions for treating iron disorders
CN112778155B (zh) 2019-11-11 2023-08-11 大连万春布林医药有限公司 妥卡雷琐衍生物及其用途
KR20230006568A (ko) 2020-05-04 2023-01-10 비욘드스프링 파마수티컬스, 인코포레이티드. 낮은 면역원성을 갖는 암에서 암세포 사멸을 강화하기 위한 삼중 병용 요법
US20240197723A1 (en) 2021-04-09 2024-06-20 Beyondspring Pharmaceuticals, Inc. Therapeutic compositions and methods for treating tumors
CN115703763A (zh) 2021-08-13 2023-02-17 大连万春布林医药有限公司 普那布林或其制剂中的杂质及其用途
CA3234699A1 (en) 2021-10-07 2023-04-13 Beyondspring Pharmaceuticals, Inc. Methods for treating cancers and tumors

Also Published As

Publication number Publication date
MX2018015100A (es) 2019-09-04
IL263439A (en) 2019-01-31
CN118304304A (zh) 2024-07-09
RU2018142394A (ru) 2020-07-10
EP3463337A4 (en) 2020-02-12
EP3463337A1 (en) 2019-04-10
RU2018142394A3 (es) 2020-08-18
IL263439B2 (en) 2025-06-01
TW201801726A (zh) 2018-01-16
KR20240091084A (ko) 2024-06-21
AU2017278245A1 (en) 2018-12-20
RU2760348C2 (ru) 2021-11-24
JP7405881B2 (ja) 2023-12-26
US20190175587A1 (en) 2019-06-13
JP2024028993A (ja) 2024-03-05
US20220143013A1 (en) 2022-05-12
CN109475524A (zh) 2019-03-15
WO2017214052A1 (en) 2017-12-14
JP2022058964A (ja) 2022-04-12
AU2017278245B2 (en) 2022-09-15
SG11201810872UA (en) 2019-01-30
BR112018074990A2 (pt) 2019-03-12
TWI777957B (zh) 2022-09-21
KR20190015361A (ko) 2019-02-13
JP2019521180A (ja) 2019-07-25
US12433886B2 (en) 2025-10-07
NZ748877A (en) 2020-11-27
KR20230018545A (ko) 2023-02-07
US11229642B2 (en) 2022-01-25
JP7025416B2 (ja) 2022-02-24
IL263439B1 (en) 2025-02-01
CA3026455A1 (en) 2017-12-14
MX389200B (es) 2025-03-20

Similar Documents

Publication Publication Date Title
CL2018003489A1 (es) Composición y método para reducir neutropenia
CL2020000060A1 (es) Compuestos antiproliferativos y métodos para utilizarlos.
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CY1121750T1 (el) Cot διαμορφωτες και μεθοδοι χρησης αυτων
CL2018002532A1 (es) Composición farmacéutica que comprende empagliflozina y sus usos
GT201600185A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
ECSP18008905A (es) Tricíclicos sustituidos y método para usarlos.
CL2018000739A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d y artículos de la misma.
CL2017000285A1 (es) Terapia combinada para el tratamiento de un paramixovirus
CL2016000839A1 (es) Composiciones para modular la expresión de c9orf72.
MX2022010805A (es) Metodo para reducir la neutropenia.
EA201692105A1 (ru) Новые пиразолопиримидиновые производные и их применение в качестве ингибиторов malt1
MX2015010312A (es) Metodos para tratamiento del melanoma.
BR112017018620A2 (pt) método de administração de tradipitanto, e, tradipitanto.
MX377544B (es) Composiciones topicas que comprenden un corticosteroide y un retinoide para tratar psoriasis.
MX2017005555A (es) Inhibidores del bromodominio.
BR112017018420A2 (pt) composição curável
CL2015002180A1 (es) Terapia de combinación para el tratamiento de neumonía nosocomial
MX2017001352A (es) Derivados de pirrolidinona como inhibidores de metionina aminopeptidasa 2 (metap-2).
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
CL2016001098A1 (es) Uso de cisteamina y sus derivados para el tratamiento de enfermedades mitocondriales
DOP2018000034A (es) Combinaciones de un anticuerpo ox40 y un modulador de tlr4 y usos de las mismas
MX385447B (es) Agente antihipertensivo
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.